Hospital
Lancaster General Hospital
Lancaster General Hospital was paid $33.78M by Medicaid between Jan 2018 and Dec 2024, across 502 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoLANCASTER GENERAL HOSPITAL
LANCASTER, PA 17602
LANCASTER, PA 17602
33aNPI1104875103assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$33.78M
24GClaims1,090,420
24DCodes billed502
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#6 of 154
Median peer was paid$2.82M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELCH, GARY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,882 | $126K | |
| 2019 | 5,594 | $162K | |
| 2020 | 146,765 | $3.99M | |
| 2021 | 513,904 | $15.09M | |
| 2022 | 151,784 | $4.87M | |
| 2023 | 147,744 | $4.48M | |
| 2024incomplete | 122,747 | $5.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 44,199 | 42,669 | $4.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 42,329 | 40,907 | $4.32M |
| G0378 | Hospital observation service, per hour | 9.9% | 4,308 | 4,108 | $3.35M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.3% | 41,674 | 39,244 | $3.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.4% | 26,033 | 25,302 | $2.84M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 3.5% | 31,291 | 8,984 | $1.17M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.2% | 444 | 361 | $1.10M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 10,111 | 9,956 | $709K |
| 80053 | Comprehensive metabolic panel | 1.9% | 79,566 | 73,621 | $644K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 4,171 | 4,033 | $508K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.4% | 11,418 | 8,257 | $473K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.2% | 7,664 | 7,447 | $415K |
490 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.2% | 10,739 | $401K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 3,943 | $389K |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.1% | 7,460 | $370K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,983 | $317K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,696 | $283K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,884 | $260K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,108 | $220K |
| 87536 | <1% | 1,874 | $211K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,534 | $204K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,296 | $193K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,460 | $193K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,782 | $193K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,207 | $168K |
| 80050 | General health panel | <1% | 3,679 | $165K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,934 | $162K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,753 | $161K |
| 36415 | Collection of venous blood by venipuncture | <1% | 67,340 | $160K |
| 80061 | Lipid panel | <1% | 11,134 | $153K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,708 | $149K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,704 | $149K |
| X0621 | <1% | 598 | $137K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,842 | $130K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,778 | $129K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,819 | $121K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,625 | $114K |
| 0225U | <1% | 1,163 | $100K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 363 | $94K |
| 95811 | <1% | 213 | $92K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,671 | $86K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,191 | $85K |
| 76830 | Ultrasound, transvaginal | <1% | 1,940 | $81K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,530 | $81K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,237 | $75K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,281 | $75K |
| 84484 | <1% | 11,107 | $74K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,728 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,951 | $72K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 40 | $71K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,574 | $69K |
| 76801 | <1% | 1,741 | $69K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,156 | $67K |
| 85027 | <1% | 10,739 | $65K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,691 | $63K |
| 87088 | <1% | 9,250 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,138 | $60K |
| 93971 | <1% | 1,104 | $57K | |
| 76821 | <1% | 1,037 | $54K | |
| 47562 | <1% | 81 | $54K | |
| 86803 | <1% | 2,812 | $54K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 870 | $53K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,284 | $51K |
| 77066 | Tomosynthesis, mammo | <1% | 601 | $51K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 122 | $50K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 952 | $50K |
| 78830 | <1% | 195 | $49K | |
| 80081 | <1% | 677 | $49K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,105 | $49K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,382 | $49K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,861 | $45K |
| 76813 | <1% | 839 | $44K | |
| 87150 | <1% | 827 | $42K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 289 | $42K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,367 | $42K |
| 86480 | <1% | 616 | $42K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,779 | $39K |
| 76642 | <1% | 946 | $39K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 523 | $38K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 191 | $36K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 710 | $36K |
| 62323 | <1% | 102 | $36K | |
| 84466 | <1% | 2,339 | $36K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,861 | $33K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,948 | $33K |
| 83690 | <1% | 10,306 | $32K | |
| 76770 | <1% | 804 | $32K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 335 | $31K |
| 93970 | <1% | 451 | $31K | |
| 87480 | <1% | 1,370 | $31K | |
| 96417 | <1% | 481 | $30K | |
| 87660 | <1% | 1,365 | $30K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,223 | $29K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 558 | $28K |
| 82607 | <1% | 2,504 | $27K | |
| 76536 | <1% | 604 | $26K | |
| 81001 | <1% | 13,213 | $26K | |
| 82728 | <1% | 2,388 | $26K | |
| 83970 | <1% | 686 | $26K | |
| 76820 | <1% | 958 | $25K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 88 | $24K |
| 84702 | <1% | 1,632 | $24K | |
| 77065 | Tomosynthesis, mammo | <1% | 380 | $24K |
| 72110 | <1% | 1,244 | $23K | |
| 83735 | <1% | 4,609 | $23K | |
| 87522 | Neg quan hep c or qual rna | <1% | 596 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,632 | $23K |
| 83880 | <1% | 904 | $22K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 288 | $22K |
| 93226 | <1% | 613 | $21K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 814 | $21K |
| 70486 | <1% | 392 | $21K | |
| 93017 | <1% | 607 | $21K | |
| 87077 | <1% | 3,368 | $21K | |
| 71250 | <1% | 360 | $20K | |
| 76818 | <1% | 345 | $20K | |
| 82570 | <1% | 2,912 | $20K | |
| 73630 | <1% | 1,953 | $20K | |
| 87186 | <1% | 2,848 | $19K | |
| 77336 | <1% | 447 | $19K | |
| 83655 | <1% | 1,718 | $19K | |
| 86317 | <1% | 811 | $19K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 50 | $18K |
| 84403 | <1% | 672 | $18K | |
| 83540 | <1% | 2,379 | $18K | |
| 86003 | <1% | 338 | $18K | |
| 96415 | <1% | 543 | $18K | |
| 85610 | <1% | 6,146 | $18K | |
| 84439 | <1% | 2,258 | $17K | |
| 81025 | <1% | 6,639 | $17K | |
| 87631 | <1% | 146 | $17K | |
| 87641 | <1% | 661 | $17K | |
| 86235 | <1% | 480 | $16K | |
| 74018 | <1% | 1,140 | $16K | |
| 87340 | <1% | 1,213 | $16K | |
| 82747 | <1% | 740 | $16K | |
| 86255 | <1% | 474 | $16K | |
| 86850 | <1% | 2,246 | $15K | |
| 73560 | <1% | 1,084 | $15K | |
| 94729 | <1% | 568 | $15K | |
| 85379 | <1% | 2,095 | $15K | |
| 82043 | <1% | 1,888 | $15K | |
| 86038 | <1% | 988 | $15K | |
| 84703 | <1% | 2,119 | $14K | |
| 87040 | <1% | 1,809 | $14K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 382 | $14K |
| 94726 | <1% | 565 | $14K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 324 | $14K |
| 74178 | <1% | 78 | $14K | |
| 73610 | <1% | 929 | $14K | |
| 86618 | <1% | 602 | $14K | |
| 72050 | <1% | 595 | $14K | |
| 81329 | <1% | 128 | $13K | |
| 73030 | <1% | 1,061 | $13K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,847 | $13K |
| 81003 | <1% | 6,170 | $13K | |
| 450 | Pov group 1 hd 301-450 lbs | <1% | 21 | $13K |
| 77062 | <1% | 570 | $12K | |
| 84153 | <1% | 541 | $12K | |
| 64493 | <1% | 32 | $12K | |
| 73130 | <1% | 1,167 | $12K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 230 | $12K |
| 84146 | <1% | 469 | $11K | |
| 82784 | <1% | 773 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,429 | $11K |
| 86140 | <1% | 3,919 | $11K | |
| 80076 | <1% | 1,230 | $11K | |
| 76870 | <1% | 254 | $11K | |
| 84402 | <1% | 381 | $10K | |
| 96411 | <1% | 223 | $10K | |
| 93225 | <1% | 608 | $10K | |
| 10060 | <1% | 100 | $10K | |
| 86160 | <1% | 502 | $10K | |
| 77080 | <1% | 215 | $10K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 440 | $10K |
| 70491 | <1% | 167 | $10K | |
| 86704 | <1% | 692 | $10K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 594 | $10K |
| 73502 | <1% | 620 | $9K | |
| 72131 | <1% | 198 | $9K | |
| 86706 | <1% | 762 | $9K | |
| 77334 | <1% | 122 | $9K | |
| 81596 | <1% | 160 | $9K | |
| 86592 | <1% | 2,310 | $9K | |
| 73564 | <1% | 647 | $9K | |
| 85730 | <1% | 2,187 | $9K | |
| 44970 | <1% | 12 | $9K | |
| 84481 | <1% | 379 | $9K | |
| 49083 | <1% | 18 | $9K | |
| 86901 | <1% | 2,420 | $8K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 480 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,389 | $8K |
| 86900 | <1% | 2,426 | $8K | |
| 87640 | <1% | 455 | $8K | |
| 85652 | <1% | 2,889 | $8K | |
| 77412 | <1% | 258 | $8K | |
| 86787 | <1% | 472 | $8K | |
| 84100 | <1% | 1,635 | $8K | |
| 83001 | <1% | 442 | $8K | |
| G9012 | Other specified case management service not elsewhere classified | <1% | 42 | $8K |
| 96376 | <1% | 1,470 | $8K | |
| 82670 | <1% | 336 | $7K | |
| 76857 | <1% | 568 | $7K | |
| 72070 | <1% | 430 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,602 | $7K |
| 12001 | <1% | 186 | $7K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 374 | $7K |
| 72100 | <1% | 406 | $7K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 69 | $7K |
| 80164 | <1% | 404 | $7K | |
| 75574 | <1% | 37 | $6K | |
| 88342 | <1% | 371 | $6K | |
| 77061 | <1% | 283 | $6K | |
| 94060 | <1% | 678 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 52 | $6K |
| 86708 | <1% | 418 | $6K | |
| 87510 | <1% | 848 | $6K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 64 | $6K |
| 86431 | <1% | 724 | $6K | |
| 83605 | <1% | 1,553 | $5K | |
| 80197 | <1% | 375 | $5K | |
| 19083 | <1% | 12 | $5K | |
| 87625 | <1% | 181 | $5K | |
| 96402 | <1% | 128 | $5K | |
| 82565 | <1% | 1,002 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 801 | $5K |
| 73110 | <1% | 545 | $5K | |
| 59025 | Fetal non-stress test | <1% | 599 | $5K |
| 84145 | <1% | 518 | $5K | |
| 90715 | <1% | 1,191 | $5K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 576 | $5K |
| 87070 | <1% | 894 | $5K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 56 | $5K |
| 93798 | <1% | 212 | $5K | |
| 83002 | <1% | 289 | $5K | |
| 82550 | <1% | 892 | $5K | |
| 43235 | <1% | 38 | $5K | |
| 92551 | <1% | 636 | $5K | |
| 90686 | <1% | 1,174 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 916 | $4K |
| 72128 | <1% | 80 | $4K | |
| T1028 | Assessment of home, physical and family environment, to determine suitability to meet patient's medical needs | <1% | 64 | $4K |
| 82950 | <1% | 591 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 51 | $4K |
| 12011 | <1% | 109 | $4K | |
| 96367 | <1% | 391 | $4K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 202 | $4K |
| 73590 | <1% | 295 | $4K | |
| 84165 | <1% | 319 | $4K | |
| 86696 | <1% | 157 | $4K | |
| 84156 | <1% | 948 | $4K | |
| 82803 | <1% | 299 | $4K | |
| 86200 | <1% | 251 | $4K | |
| 99173 | <1% | 643 | $3K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 40 | $3K |
| 86709 | <1% | 240 | $3K | |
| 71271 | <1% | 72 | $3K | |
| 82105 | <1% | 182 | $3K | |
| 82248 | <1% | 470 | $3K | |
| 86695 | <1% | 157 | $3K | |
| 82962 | <1% | 4,643 | $3K | |
| 84550 | <1% | 556 | $3K | |
| 87205 | <1% | 884 | $3K | |
| 86665 | <1% | 111 | $3K | |
| 71101 | <1% | 281 | $3K | |
| 12002 | <1% | 56 | $3K | |
| 95816 | <1% | 280 | $3K | |
| 78306 | <1% | 55 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 121 | $3K |
| 86039 | <1% | 190 | $3K | |
| 86376 | <1% | 339 | $3K | |
| 29125 | <1% | 139 | $3K | |
| 86361 | <1% | 91 | $3K | |
| 82247 | <1% | 373 | $3K | |
| 82533 | <1% | 210 | $3K | |
| 83721 | <1% | 322 | $3K | |
| 82746 | <1% | 266 | $3K | |
| 97597 | <1% | 117 | $2K | |
| 74022 | <1% | 164 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 28 | $2K |
| 83021 | <1% | 166 | $2K | |
| 80069 | <1% | 297 | $2K | |
| 87493 | <1% | 63 | $2K | |
| 87329 | <1% | 189 | $2K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 123 | $2K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,826 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,672 | $2K |
| 86762 | <1% | 119 | $2K | |
| 93243 | <1% | 66 | $2K | |
| 82378 | <1% | 148 | $2K | |
| 83993 | <1% | 108 | $2K | |
| 83615 | <1% | 409 | $2K | |
| 93325 | <1% | 185 | $2K | |
| 72040 | <1% | 148 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,039 | $2K |
| 80178 | <1% | 304 | $2K | |
| 73080 | <1% | 265 | $2K | |
| 85018 | <1% | 831 | $2K | |
| 86800 | <1% | 115 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 16,790 | $2K |
| 73140 | <1% | 260 | $2K | |
| 84590 | <1% | 150 | $2K | |
| 82947 | <1% | 532 | $2K | |
| 88341 | <1% | 96 | $2K | |
| 87427 | <1% | 147 | $2K | |
| 36591 | <1% | 188 | $2K | |
| 88312 | <1% | 44 | $2K | |
| 73090 | <1% | 192 | $2K | |
| 93242 | <1% | 66 | $2K | |
| 76827 | <1% | 42 | $2K | |
| 29515 | <1% | 63 | $2K | |
| 87902 | <1% | 15 | $2K | |
| 85576 | <1% | 111 | $2K | |
| 76882 | <1% | 247 | $2K | |
| 80177 | <1% | 115 | $1K | |
| 0297T | <1% | 52 | $1K | |
| 82310 | <1% | 205 | $1K | |
| 78264 | <1% | 13 | $1K | |
| 86664 | <1% | 68 | $1K | |
| 73522 | <1% | 62 | $1K | |
| 83020 | <1% | 114 | $1K | |
| 86308 | <1% | 194 | $1K | |
| 87045 | <1% | 167 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 12 | $1K |
| 51798 | <1% | 238 | $1K | |
| 87517 | <1% | 30 | $1K | |
| 72082 | <1% | 28 | $1K | |
| 86663 | <1% | 68 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,365 | $1K |
| 80175 | <1% | 93 | $1K | |
| 87075 | <1% | 197 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,429 | $1K |
| 77290 | <1% | 17 | $1K | |
| 0296T | <1% | 52 | $1K | |
| 84425 | <1% | 146 | $1K | |
| 82330 | <1% | 197 | $1K | |
| 83516 | <1% | 780 | $1K | |
| 82010 | <1% | 390 | $995.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,502 | $974.09 |
| 88304 | <1% | 486 | $962.60 | |
| 70496 | <1% | 13 | $957.30 | |
| 82150 | <1% | 202 | $940.69 | |
| 70498 | <1% | 12 | $920.92 | |
| 87015 | <1% | 141 | $908.86 | |
| 82785 | <1% | 53 | $908.37 | |
| 77300 | <1% | 17 | $904.16 | |
| 76825 | <1% | 42 | $903.45 | |
| 82627 | <1% | 39 | $901.95 | |
| 86765 | <1% | 64 | $852.03 | |
| 94618 | <1% | 165 | $848.13 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 45 | $831.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 258 | $826.76 |
| 97014 | <1% | 51 | $807.12 | |
| 84480 | <1% | 102 | $782.45 | |
| 86780 | <1% | 54 | $776.26 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,316 | $760.45 |
| 85044 | <1% | 211 | $722.76 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,295 | $721.98 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,856 | $712.15 |
| 73060 | <1% | 79 | $673.92 | |
| 73552 | <1% | 57 | $660.44 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 1,745 | $641.45 |
| 82951 | <1% | 63 | $619.45 | |
| 94760 | <1% | 372 | $615.63 | |
| 85014 | <1% | 360 | $608.57 | |
| 84132 | <1% | 200 | $608.22 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 397 | $597.66 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,943 | $588.73 |
| 84432 | <1% | 27 | $579.88 | |
| 88307 | <1% | 229 | $555.30 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 140 | $543.45 |
| 87046 | <1% | 187 | $538.26 | |
| 74220 | <1% | 25 | $528.79 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 117 | $528.00 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,653 | $521.26 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,909 | $520.79 |
| 87255 | <1% | 14 | $511.69 | |
| 77280 | <1% | 16 | $502.13 | |
| 76942 | <1% | 92 | $479.84 | |
| 82731 | <1% | 26 | $454.00 | |
| 86617 | <1% | 25 | $436.12 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 572 | $412.96 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 506 | $385.79 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,449 | $384.64 |
| 86300 | <1% | 14 | $381.25 | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,870 | $368.02 |
| 84305 | <1% | 14 | $365.10 | |
| 93350 | <1% | 12 | $362.04 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 230 | $355.76 |
| 96368 | <1% | 44 | $355.49 | |
| 82652 | <1% | 14 | $345.44 | |
| 84155 | <1% | 84 | $333.43 | |
| 86870 | <1% | 42 | $329.02 | |
| 86304 | <1% | 14 | $325.58 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,877 | $322.51 |
| 86334 | <1% | 13 | $314.59 | |
| 82140 | <1% | 71 | $311.41 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,101 | $310.65 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 464 | $306.23 |
| 300 | Patient transfer system <300 | <1% | 16 | $302.60 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,659 | $295.25 |
| 90656 | <1% | 48 | $291.04 | |
| 87081 | <1% | 49 | $277.15 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,824 | $276.43 |
| 87209 | <1% | 12 | $273.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,157 | $270.61 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 30 | $250.31 |
| 72202 | <1% | 14 | $243.72 | |
| 84295 | <1% | 93 | $227.28 | |
| 84445 | <1% | 12 | $222.00 | |
| 74230 | <1% | 13 | $220.60 | |
| 72220 | <1% | 12 | $207.58 | |
| 99152 | <1% | 85 | $205.56 | |
| 84630 | <1% | 14 | $202.58 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 165 | $199.60 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 43 | $199.03 |
| 84460 | <1% | 29 | $194.74 | |
| 93308 | <1% | 13 | $189.44 | |
| 86920 | <1% | 19 | $175.35 | |
| 93321 | <1% | 25 | $164.47 | |
| 36600 | <1% | 42 | $163.79 | |
| 88302 | <1% | 71 | $163.25 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 134 | $160.86 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,112 | $154.90 |
| 73070 | <1% | 13 | $154.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,660 | $152.05 |
| 83525 | <1% | 13 | $147.40 | |
| 70360 | <1% | 17 | $143.00 | |
| 84244 | <1% | 13 | $135.54 | |
| 87272 | <1% | 71 | $120.73 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 186 | $119.05 |
| 84436 | <1% | 12 | $113.52 | |
| 88311 | <1% | 112 | $108.64 | |
| 86593 | <1% | 16 | $107.77 | |
| 51702 | <1% | 25 | $105.21 | |
| 87177 | <1% | 12 | $102.04 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,013 | $96.48 |
| 3078F | <1% | 51 | $90.00 | |
| C1769 | Guide wire | <1% | 160 | $86.00 |
| 72170 | <1% | 13 | $74.50 | |
| 86682 | <1% | 58 | $74.40 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 550 | $71.83 |
| 83883 | <1% | 23 | $71.15 | |
| 3074F | <1% | 57 | $70.00 | |
| 84520 | <1% | 15 | $69.62 | |
| 87338 | <1% | 39 | $67.55 | |
| 89051 | <1% | 14 | $54.25 | |
| L3260 | Surgical boot/shoe, each | <1% | 14 | $43.86 |
| 83520 | <1% | 16 | $42.23 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 384 | $29.40 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 51 | $24.39 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 102 | $23.04 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,539 | $22.24 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 193 | $12.17 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 371 | $9.72 |
| 99153 | Mod sedat endo service >5yrs | <1% | 14 | $9.16 |
| 87449 | <1% | 13 | $8.04 | |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 26 | $6.79 |
| A9270 | Non-covered item or service | <1% | 496 | $5.15 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,159 | $2.65 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 21 | $2.30 |
| J3490 | Unclassified drugs | <1% | 97 | $0.40 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 44 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 427 | $0.00 |
| 90651 | 0% | 103 | $0.00 | |
| 90677 | 0% | 107 | $0.00 | |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 0% | 34 | $0.00 |
| 90647 | 0% | 67 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 40 | $0.00 |
| 97162 | 0% | 14 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 14 | $0.00 |
| 90723 | 0% | 62 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 64 | $0.00 |
| 90792 | Psychiatric diagnostic evaluation with medical services | 0% | 21 | $0.00 |
| 90680 | 0% | 48 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 38 | $0.00 |
| 90620 | 0% | 18 | $0.00 | |
| J1836 | Injection, metronidazole, 10 mg | 0% | 26 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 59 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| 90696 | 0% | 15 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,023 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 428 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 295 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 47 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 24 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 208 | $0.00 |
| 90734 | 0% | 122 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 456 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 64 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 52 | $0.00 |
| 90633 | 0% | 38 | $0.00 | |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 38 | $0.00 |
| 90670 | 0% | 77 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 247 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 23 | $0.00 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 663 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 27 | $0.00 |
| 90710 | 0% | 14 | $0.00 | |
| 90707 | 0% | 12 | $0.00 | |
| 90700 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELCH, GARY (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | $882K |
| Lancaster General Hospital | Quarryville, PA | $630K |
| Lancaster General Hospital | Lancaster, PA | $381K |
| Lancaster General Medical Group | Ephrata, PA | $320K |
| Lancaster General Hospital | Lancaster, PA | $299K |
| Lancaster General Hospital | Lancaster, PA | $289K |
| Lancaster General Medical Group | Lancaster, PA | $192K |
| Lancaster General Hospital | Lancaster, PA | $189K |
| Lancaster General Hospital | Lancaster, PA | $187K |
| Lancaster General Hospital | Lancaster, PA | $176K |
| Lancaster General Hospital | Lancaster, PA | $174K |
| Lancaster General Hospital | Lancaster, PA | $168K |
| Lancaster General Hospital | Lancaster, PA | $155K |
| Lancaster General Hospital | Lancaster, PA | $150K |
| Lancaster General Hospital | Lancaster, PA | $79K |
| Lancaster General Hospital | Parkesburg, PA | $60K |
| Lancaster General Hospital | Lancaster, PA | $45K |
| Lancaster General Hospital | Lancaster, PA | $42K |
| Lancaster General Hospital | Lancaster, PA | $29K |
| Lancaster General Hospital | Lancaster, PA | $29K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.